Dr. Richard Goldfarb, MD
What this data tells you about Dr. Goldfarb
Dr. Richard Goldfarb is an urology physician in Houston, TX, with 19 years in practice. Based on federal Medicare data, Dr. Goldfarb performed 12,064 Medicare services across 3,402 unique beneficiaries.
Between the years covered by Open Payments, Dr. Goldfarb received a total of $8,880 from 62 pharmaceutical and/or device companies across 391 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Goldfarb is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| BCG treatment for bladder cancer | 2,750 | $2 | $3 |
| Denosumab injection (Prolia/Xgeva) | 2,460 | $19 | $24 |
| Office visit, established patient (30-39 min) | 1,455 | $93 | $134 |
| Automated urinalysis | 1,429 | $2 | $2 |
| Chronic care management, first 20 min/month | 1,084 | $47 | $65 |
| Blood draw (venipuncture) | 868 | $8 | $8 |
| Leuprolide injectable, camcevi, 1 mg | 840 | $65 | $83 |
| Bladder ultrasound after voiding | 312 | $8 | $11 |
| Office visit, established patient (20-29 min) | 294 | $70 | $94 |
| Diagnostic exam of bladder and urethra using an endoscope | 101 | $62 | $253 |
| New patient office visit (45-59 min) | 80 | $117 | $176 |
| Instillation of anti-cancer drug into bladder | 57 | $70 | $95 |
| Drug injection, under skin or into muscle | 46 | $11 | $15 |
| Office visit, established patient, complex (40-54 min) | 38 | $140 | $184 |
| Ultrasound scan of pelvic region through rectum | 31 | $26 | $33 |
| Electronic assessment of bladder emptying | 29 | $8 | $15 |
| Biopsy of prostate gland | 27 | $103 | $250 |
| Ct scan of abdomen and pelvis without contrast | 27 | $85 | $116 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $26 | $35 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 22 | $574 | $794 |
| Simple bladder irrigation and/or instillation | 20 | $63 | $79 |
| Ultrasonic guidance for needle placement | 18 | $25 | $31 |
| Complete ultrasound scan behind abdominal cavity | 15 | $49 | $103 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 13 | $4 | $7 |
| New patient office visit, complex (60-74 min) | 13 | $179 | $227 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 12 | $340 | $425 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | — Not enrolled | N/A |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Goldfarb is a clinical cardiology specialist, with above-average Medicare volume (top 8% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Goldfarb experienced with bcg treatment for bladder cancer?
Does Dr. Goldfarb receive payments from pharmaceutical companies?
How do Dr. Goldfarb's costs compare to other urology physicians in Houston?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology